Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZMFX6)

Drug Name
KU-1257 Drug Info
Synonyms
Dalcotidine; 120958-90-9; UNII-9968S2UKFJ; KU-1257; KU 1257; 9968S2UKFJ; NCGC00182982-01; Dalcotidine [INN]; Dalcotidine (JAN/INN); AC1L2VE9; DSSTox_RID_83001; DSSTox_CID_28732; DSSTox_GSID_48806; CHEMBL311206; SCHEMBL1815082; N-Ethyl-N'-(3-(3-(piperidinomethyl)phenoxy)propyl)urea; DTXSID4048806; CHEBI:31454; 1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea; ZINC1889603; Tox21_113283; BDBM50406670; CAS-120958-90-9; D01698; L002431; A1-04840; 1-Ethyl-3-(3-((alpha-piperidino-m-tolyl)oxy)propyl)urea; Urea, N-ethyl-N'-(3-(3-(1-p
Indication
Disease Entry ICD 11 Status REF
Duodenal ulcer DA63 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
129319
ChEBI ID
CHEBI:31454
CAS Number
CAS 120958-90-9
TTD Drug ID
DMZMFX6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histamine H2 receptor (H2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [3]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [4]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [4]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [5]
Betazole DMUFGAY Gastric secretory disorder DD90 Approved [6]
Ebrotidine DMV5KR3 Duodenal ulcer DA63 Withdrawn from market [7]
Pibutidine DMXSTRM Ulcerative colitis DD71 Discontinued in Phase 3 [8]
Osutidine DMN7TL8 Duodenal ulcer DA63 Discontinued in Phase 3 [9]
Lavoltidine DMTY5VE Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [10]
IGN-2098 DMU4N1O Duodenal ulcer DA63 Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001852)
2 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
3 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
4 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
5 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
6 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
7 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
8 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
9 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
10 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
11 Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.